Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AstriVax
- Development stage
- Preclinical
- Lead developer
- AstriVax Therapeutics
- Modality
- Viral Vectors → Gene Addition/Replacement → Gene Therapies, DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
AstriVax refers to a pipeline of vaccine candidates, most notably a therapeutic vaccine for chronic hepatitis B, developed using the proprietary Plasmid Launched Live Attenuated Virus (PLLAV) platform. Developed by the KU Leuven spin-off AstriVax, this technology utilizes a DNA plasmid to deliver the genetic blueprint of a live attenuated virus, specifically the yellow fever YF17D strain. Once administered, the plasmid enters host cells and "launches" the replication of the attenuated virus, which has been engineered to express target antigens from the hepatitis B virus (HBV). This approach combines the stability and ease of manufacturing associated with DNA vaccines with the high immunogenicity and comprehensive immune activation (including both T-cell and B-cell responses) characteristic of live attenuated vaccines. The platform is also being utilized to develop a more stable, cold-chain independent prophylactic vaccine for yellow fever.
- Other names
- AstriVax HBV vaccineAstriVax therapeutic HBV vaccine
02
Targets
HBV antigens (Hepatitis B virus antigens)
Beyond the preview
Go deeper on AstriVax.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AstriVax.